» Articles » PMID: 26719644

Tissue and Serum Inflammatory Cytokine Levels in Korean Psoriasis Patients: A Comparison Between Plaque and Guttate Psoriasis

Overview
Journal Ann Dermatol
Specialty Dermatology
Date 2016 Jan 1
PMID 26719644
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The phenotypic heterogeneity of psoriasis could be explained by the alternate activation of either T-helper (Th)-1- or Th-17-related cytokines. However, evidence directly supporting this hypothesis is scarce.

Objective: To characterize the expression of Th-1- and Th-17-related cytokines according to the morphological psoriasis phenotype: guttate vs. plaque.

Methods: In this study, we enrolled 68 patients exhibiting either guttate or plaque psoriasis, and 10 healthy controls. To avoid age-related bias, age matching was performed for each group. Circulating levels of interferon (IFN)-γ, interleukin (IL)-1RA, IL-2, IL-12p40, IL-17A, IL-22, and IL-23 were measured with an enzyme-linked immunosorbent assay (ELISA). Psoriasis-affected tissue was obtained through biopsy sampling from the eight patients who exhibited the most typical morphology. Levels of IL-1RA, IL-12p40, IL-17, IL-22, and IL-23 in the psoriasis tissue samples were measured with western blot analysis.

Results: ELISAs of the serum samples showed higher levels of inflammatory cytokines such as IL-1RA, IL-2, IL-23, and IFN-γ in patients with psoriasis than in healthy controls. However, the inflammatory cytokine levels did not differ significantly between guttate and plaque psoriasis patients. Western blot analysis of psoriatic tissue revealed higher protein levels of Th-1- and Th-17-related cytokines in patients than in healthy controls. The levels of IL-12p40 and IL-23 were unexpectedly higher in plaque tissue than in guttate tissue.

Conclusion: The morphological phenotype of psoriasis does not appear to be determined by a specific activation of either the Th-1 or Th-17 pathway. Rather, the cytokine profile influences disease activity and is altered according to the status of the lesion (early or chronic).

Citing Articles

Development and Evaluation of Methotrexate and Baicalin-Loaded Nanolipid Carriers for Psoriasis Treatment.

Sohail S, Arshad S, Khalid S, Dar M, Iqbal K, Sohail H Turk J Pharm Sci. 2024; 21(4):327-339.

PMID: 39224396 PMC: 11589095. DOI: 10.4274/tjps.galenos.2023.71242.


Bioinformatic Analysis of the Potential Common Pathogenic Mechanisms for Psoriasis and Metabolic Syndrome.

Zhou Y, Han L, Wang Z, Fang R, Wan Y, Yang Z Inflammation. 2023; 46(4):1381-1395.

PMID: 37222907 DOI: 10.1007/s10753-023-01815-4.


Cytokine Profiles and the Relationship of Disease Severity in Patients with Psoriasis.

Wang Q, Yan D, Zheng S, Li M, Li J, Fu X Indian J Dermatol. 2022; 67(2):204.

PMID: 36092198 PMC: 9455096. DOI: 10.4103/ijd.ijd_79_22.


Comparison of Th1 and Th17 Inflammatory Cytokine Profiles Between Chronic Plaque and Acute Guttate Psoriasis.

Ju H, Park H, Choi I, Lee K, Kwon M, Park C Ann Dermatol. 2022; 34(3):200-205.

PMID: 35721337 PMC: 9171175. DOI: 10.5021/ad.2022.34.3.200.


Evaluation of Serum Proinflammatory Cytokine IL-17A and Tight Junction Protein Claudin-1 in Psoriasis.

Xu L, Pan Y, Tang S, Bai J, Wu Y, Qiao J Contrast Media Mol Imaging. 2022; 2022:6092808.

PMID: 35340911 PMC: 8920681. DOI: 10.1155/2022/6092808.


References
1.
Johnston A, Gudjonsson J, Sigmundsdottir H, Love T, Valdimarsson H . Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol. 2004; 138(1):83-93. PMC: 1809187. DOI: 10.1111/j.1365-2249.2004.00600.x. View

2.
Bos J . The pathomechanisms of psoriasis; the skin immune system and cyclosporin. Br J Dermatol. 1988; 118(2):141-55. DOI: 10.1111/j.1365-2133.1988.tb01768.x. View

3.
Zaba L, Fuentes-Duculan J, Eungdamrong N, Abello M, Novitskaya I, Pierson K . Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2008; 129(1):79-88. PMC: 2701224. DOI: 10.1038/jid.2008.194. View

4.
Lowes M, Bowcock A, Krueger J . Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130):866-73. DOI: 10.1038/nature05663. View

5.
Choe Y, Hwang Y, Hahn H, Jung J, Jung H, Lee Y . A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis. Br J Dermatol. 2012; 167(4):762-7. DOI: 10.1111/j.1365-2133.2012.11038.x. View